2024
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.
Berraondo P, Cuesta R, Sanmamed M, Melero I. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines. Cancer Discovery 2024, 14: 2021-2024. PMID: 39485256, DOI: 10.1158/2159-8290.cd-24-1196.Peer-Reviewed Original ResearchIL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, Jeon S, You S, Racke M, Bucala R, Kang I. IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination. EBioMedicine 2024, 103: 105114. PMID: 38640835, PMCID: PMC11041015, DOI: 10.1016/j.ebiom.2024.105114.Peer-Reviewed Original ResearchConceptsCD4<sup>+</sup> T cellsCOVID-19 mRNA vaccinesAntigen-specific CD4<sup>+</sup> T cell responsesT cell responsesPrimary antibody deficiencyCD4<sup>+</sup> T cell responsesT cellsIL-1R1MRNA vaccinesIL-1IgG antibodiesAntigen-specific CD4<sup>+</sup> T cellsCD4+ T cell responsesLevels of IL-1R1Human CD4<sup>+</sup> T cellsIL-1 receptor 1Healthy individualsDose of COVID-19 mRNA vaccineAntigen-specific CD4IL-1R1 expressionT cell immunityRepetitive antigenic stimulationCytokines interleukin (IL)-1Immune response to virusesExpression of IL-1R1
2019
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection
Dropulic L, Oestreich M, Pietz H, Laing K, Hunsberger S, Lumbard K, Garabedian D, Turk S, Chen A, Hornung R, Seshadri C, Smith M, Hosken N, Phogat S, Chang L, Koelle D, Wang K, Cohen J. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. The Journal Of Infectious Diseases 2019, 220: 990-1000. PMID: 31058977, PMCID: PMC6688060, DOI: 10.1093/infdis/jiz225.Peer-Reviewed Original ResearchConceptsHerpes simplex virus 2T cell responsesCD4+ T cell responsesHerpes simplex virusDose of vaccinePlacebo recipientsDouble-blindCD8+ T cell responsesReplication-defective herpes simplex virusSolicited injection site reactionsHerpes simplex virus infectionThird dose of vaccineSystemic reactions to vaccinationPlacebo-controlled trialPhase 1 studyInjection site reactionsNeutralizing antibody titersPlacebo-ControlledGenital herpesThird doseSite reactionsSimplex virusVaccine recipientsNeutralizing antibodiesReactions to vaccination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply